Please login to the form below

Not currently logged in
Email:
Password:

Boehringer/ Ablynx candidate for Alzheimer's

Ablynx has announced that Boehringer Ingelheim has selected a Nanobody lead candidate for further development for treating Alzheimer's disease

Ablynx has announced that Boehringer Ingelheim has selected a Nanobody lead candidate for further development for the treatment of Alzheimer's disease.

This is the first lead candidate emerging from the Alzheimer's disease collaboration between Ablynx and Boehringer Ingelheim, and will result in a €2m milestone payment to Ablynx.

In January 2007, Boehringer Ingelheim and Ablynx announced that they had entered into a worldwide research and licensing agreement to discover and develop new therapies for Alzheimer's disease using Ablynx's Nanobodies, worth a possible $265m in milestone payments plus undisclosed royalties. Boehringer Ingelheim is solely responsible for the development, manufacture and commercialisation of any products resulting from the research collaboration.

"Ablynx's delivery of this potentially 'first-in-class' Nanobody candidate for the treatment of Alzheimer's disease highlights the speed at which we progressed from initiation of the discovery programme in 2007 to this stage of development for a very challenging target," said Dr Edwin Moses, CEO and chairman of Ablynx.

Moses added: "This lead candidate demonstrates the power of the Nanobody platform in addressing a complex disease such as Alzheimer's."

24th May 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics